Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia

European Journal of Haematology

Volumn 80, Issue 3, 2008, Pages 208-215

  Scholl, Sebastian ^a,b   Theuer, Claudia ^a   Scheble, Veit ^a   Kunert, Christa ^a   Heller, Anita ^a   Mügge, Lars Olof ^a   Fricke, Hans Joerg ^a   Höffken, Klaus ^a   Wedding, Ulrich ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Department of Internal Medicine II ^*  (Germany)

Author keywords

AML; Elderly patients; Flt3 ITD; NPM1; Prognosis

Indexed keywords

CYTARABINE; ETOPOSIDE; FLT3 LIGAND; MITOXANTRONE; NUCLEOPHOSMIN; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TANDEM REPEAT;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; GENE FREQUENCY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TANDEM REPEAT SEQUENCES;

EID: 39149134914     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.01019.x     Document Type: Article

References (35)

1. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute myeloid leukemia. Blood Rev 2004 18: 115 36.
2. Frohling S, Scholl C, Gilliland GD, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005 23: 6285 95.
3. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005 352: 254 66.
4. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996 10: 1911 8.
5. Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000 96: 3681 95.
6. Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol 2001 114: 741 60.
7. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994 263: 1281 4.
8. Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997 17: 2312 25.
9. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996 87: 882 6.
10. Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ, Carroll AJ, Morris SW. The t(3;5) (q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPMMLF1. Oncogene 1996 12: 265 75.
11. Nakagawa M, Kameoka Y, Suzuki R. Nucleophosmin in acute myelogenous leukemia (letter). N Engl J Med 2005 352: 1819 20.
12. Falini B, Bolli N, Shan J, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006 107: 4514 23.
13. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005 106: 3733 9.
14. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A, Bullinger L, Frohling S, Dohner H. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005 106: 3740 6.
15. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005 106: 3618 20.
16. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005 106: 3747 54.
17. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006 107: 4011 20.
18. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001 98: 1752 9.
19. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002 100: 59 66.
20. Thiede C, Steudel C, Mohr B, et al. Analysis of Flt3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002 99: 4326 35.
21. Stirewalt DL, Meshinchi S, Kussick SJ, Sheets KM, Pogosova-Agadjanyan E, Willman CL, Radich JP. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Br J Haematol 2004 124: 481 4.
22. Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002 21: 2555 63.
23. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001 97: 2434 9.
24. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001 113: 983 8.
25. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Dohner H, Dohner K. Prognostic significance of activating Flt3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics. a study of the AML Study Group Ulm. Blood 2002 100: 3472 4380.
26. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001 98: 1312 20.
27. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997 89: 3323 9.
28. Schoch C, Kern W, Schnittger S, Buchner T, Hiddemann W, Haferlach T. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 2004 89: 1082 90.
29. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006 108: 63 73.
30. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, Radich JP. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001 98: 3589 95.
31. Andersson A, Johansson B, Lassen C, Mitelman F, Billström R, Fioretos T. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Eur J Haematol 2004 72: 307 13.
32. Becker C, Ali HA, Krahl R, et al. High complete remission rate in patients with Acute Myeloid Leukemia (AML) above the Age of 60 Years: A report of the AML97#38 study of the East German Hematology and Oncology Study Group (OSHO). Blood 2004 104: 251a.
33. Scholl S, Mugge LO, Landt O, Loncarevic IF, Kunert C, Clement JH, Hoffken K. Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia. Leuk Res 2007 31: 1213 9.
34. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006 368: 1894 907.
35. Frohling F, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K, Dohner H. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results fromAMLSG trialAMLHD98-B. Blood 2006 108: 3280 8.